Summary & Overview

CPT 0493U: Donor-Derived Cell-Free DNA Test for Transplant Monitoring

CPT code 0493U is a Proprietary Laboratory Analyses (PLA) code that applies exclusively to the Prospera™ assay from Natera™, a next-generation sequencing laboratory test that quantifies donor-derived cell-free DNA in the plasma of transplant recipients. The code captures a clinically actionable molecular diagnostic intended to support noninvasive monitoring of organ transplant health and early detection of graft injury or rejection. Nationally, PLA codes like 0493U matter because they identify single-source diagnostics with specific clinical utility and influence coverage and billing practices for advanced molecular tests.

Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will learn the clinical context of the test, the service and typical site of service, and which payers are included in the coverage landscape. The publication provides benchmarking and policy-focused summaries relevant to billing and coverage for proprietary molecular diagnostics, summaries of payer coverage presence, and the clinical rationale for the test’s use in transplant surveillance. Data not available in the input for specific coverage policies, payment amounts, associated taxonomies, and ICD-10 diagnosis pointers are noted where applicable.

AetnaBlue Cross Blue ShieldCigna HealthUnitedHealthcareMedicare0493UCPTProprietary Laboratory Analysesdonor-derived cell-free DNAnext-generation sequencingtransplant monitoringmolecular diagnosticslaboratory test

Billing Code Overview

CPT code 0493U is a Proprietary Laboratory Analyses (PLA) code assigned specifically to the Prospera™ test from Natera™. The test uses next-generation sequencing to quantify the percentage of donor-derived cell-free DNA in the plasma of organ transplant recipients. This measurement supports monitoring transplant health by detecting and quantifying donor-derived cell-free DNA, which can indicate graft injury or rejection risk.

Service type: Laboratory molecular diagnostic test using next-generation sequencing
Typical site of service: Clinical laboratory or reference laboratory processing blood/plasma specimens

Clinical & Coding Specifications

Clinical Context

A 52-year-old kidney transplant recipient presents for routine post-transplant surveillance. The transplant team orders Prospera™ (0493U) to quantify donor-derived cell-free DNA (dd-cfDNA) in the patient’s plasma using next-generation sequencing. A phlebotomy appointment at an outpatient laboratory or hospital outpatient phlebotomy draws a blood sample into specialized tubes, which is shipped to Natera’s laboratory under chain-of-custody and temperature control. Results reporting provides a percentage of dd-cfDNA; an elevated percentage prompts correlation with clinical assessment, serum creatinine, proteinuria, viral testing, and possible biopsy to evaluate for allograft rejection or injury. Typical workflow participants include the transplant nephrologist or transplant surgeon ordering the test, outpatient clinic staff scheduling phlebotomy, a certified phlebotomist collecting the specimen at an outpatient lab or hospital outpatient department, courier services for specimen transport, and Natera laboratory personnel performing the Proprietary Laboratory Analysis.

Coding Specifications

Modifier	Description	When to Use
`00`	No modifier — default	Use when no other modifier applies to the service.
`26`	Professional component	Use if reporting only the professional component when applicable to lab consultations (rare for PLA tests).
`52`	Reduced services	Use when the test was partially performed and results are limited.
`53`	Discontinued procedure	Use if specimen collection was attempted but the procedure was terminated for patient safety.
`55`	Postoperative care only	Not typically used for this lab test; applicable if billing facility/provider only provided post-op care services tied to another procedure.
`56`	Preoperative care only	Not typical for PLA testing; use only if billing relates solely to pre-op services.
`62`	Two surgeons	Not commonly applicable; used if two physicians of same specialty performed distinct portions of a surgical service related to specimen collection.
`78`	Return to OR for related procedure during postoperative period	Not applicable to the lab test itself; included when a related surgical re-intervention occurs.
`80`	Assistant surgeon	Not applicable to the laboratory analysis but may apply to surgical services associated with transplant care.
`AS`	Physician assistant, nurse practitioner, or clinical nurse specialist service furnished under physician direction	Use when an advanced practice clinician performs specimen collection or orders under supervising physician in some payor scenarios.
`QK`	Medical direction of two, three, or four assistants	Relevant only if assistant reporting is required by payor rules for associated procedural services.
`QX`	CRNA service with medical direction by physician	Not typically used for a lab test; included for completeness when anesthesia services relate to other procedures.
`QY`	Medical direction of one certified registered nurse anesthetist	Same as above, not typical for this PLA test.
`TC`	Technical component	Use when billing only the technical component of testing (facility/lab) if separate billing from professional component applies.

Taxonomy Code	Specialty	Notes
363A00000X	Transplant Nephrology	Specialists who order and interpret dd-cfDNA for kidney transplant surveillance.
2080S0102X	Transplant Surgery	Surgeons managing transplant recipients and coordinating surveillance strategies.
207Q00000X	Clinical Pathology	Pathology/laboratory physicians who consult on test interpretation and laboratory integration.
363L00000X	Nephrology	General nephrologists managing post-transplant patients who may order this test.
334N00000X	Phlebotomy/Specimen Collection	Allied health staff performing specimen collection in outpatient or hospital settings.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`T86.10`	Kidney transplant complication, unspecified	Directly relevant for monitoring for rejection or injury after renal transplant using dd-cfDNA.
`T86.19`	Other kidney transplant complication	Captures specific non-specified complications prompting surveillance with dd-cfDNA.
`Z94.0`	Kidney transplant status	Indicates history of kidney transplant; supports medical necessity for surveillance testing.
`T86.20`	Heart transplant complication, unspecified	dd-cfDNA assays are used in multiple solid organ transplants; relevant if Prospera™ usage extends to other organ surveillance per test labeling.
`Z48.21`	Encounter for aftercare following kidney transplant	Surveillance testing during post-transplant follow-up visits.
`N18.9`	Chronic kidney disease, unspecified	Underlying renal dysfunction that may coexist and prompt closer graft monitoring.
`R94.5`	Abnormal results of kidney function studies	Lab abnormalities leading to ordering dd-cfDNA to evaluate for graft injury or rejection.
`T86.11`	Kidney transplant rejection	Definitive diagnosis that dd-cfDNA testing helps detect or rule out as part of the transplant surveillance pathway.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`36415`	Collection of venous blood by venipuncture	Routine specimen collection method used to obtain plasma for the dd-cfDNA assay prior to sending to the reference lab.
`99000`	Handling and/or conveyance of specimen for transfer from patient to lab (use when applicable by payer rules)	Used when additional specimen handling or special courier services are billed separately under payer-specific policies.
`88305`	Level IV surgical pathology, gross and microscopic examination (single organ)	May be performed if elevated dd-cfDNA prompts biopsy of the allograft and tissue evaluation is required.
`93975`	Duplex scan of renal transplant (arterial and venous)	Imaging study that can be ordered alongside dd-cfDNA testing when evaluating graft dysfunction.
`36416`	Collection of capillary blood specimen (eg, finger, heel, ear stick)	Alternative collection method in select settings; less common for dd-cfDNA which typically uses venous draws.
`80305`	Drug test, presumptive, any number of drug classes; method by immunoassay with instrumented drug toxicology confirmation	An example of ancillary laboratory testing that may be ordered concurrently to evaluate causes of allograft dysfunction or medication adherence.